Tenofovir: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
<scene name='96/960003/Cv/3'>Tenofovir diphosphate (TNV) binding site</scene> at reverse transcriptase ([[3fkb]]). Water molecules are shown as red spheres. | <scene name='96/960003/Cv/3'>Tenofovir diphosphate (TNV) binding site</scene> at reverse transcriptase ([[3fkb]]). Water molecules are shown as red spheres. | ||
<scene name='96/960003/Tnmbindingsite/ | <scene name='96/960003/Tnmbindingsite/5'>Tenofovir-monophosphate (TNM) binding site</scene> at reverse transcriptase ([[3fkb]]). | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 16:25, 16 April 2023
Tenofovir disoproxil, sold under the trade name Viread among others, is a medication used to treat chronic hepatitis B and to prevent and treat HIV/AIDS. See also [1]. Tenofovir disoproxil is a prodrug that is quickly absorbed from the gut and cleaved to release tenofovir. Inside cells, tenofovir is phosphorylated to tenofovir diphosphate (which is analogous to a triphosphate, as tenofovir itself already has one phosphonate residue), the active compound that inhibits reverse transcriptase via chain termination. at reverse transcriptase (3fkb). Water molecules are shown as red spheres. at reverse transcriptase (3fkb).
|
| ||||||||||